Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Amivantamab

Stage Phase 2

Sponsor Trisha Wise-Draper (investigator)

Route intravenous

Class EGFR x MET bispecific antibody

Mechanism EGFR and MET bispecific antibody

Target EGFR (TEC-0016)

Target MET (TEC-0123)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05074940

Amivantamab in ACC, registry NCT05074940, results posted 05.08.2026 (registry; opened 2026-10-27): n 21; ORR 1 participant; median PFS 4.6 months; serious AEs 7 of 21; FACT-HN quality of life change -0.7 (reference point not stated).

Brief source A28

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05074940

Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Amivantamab in ACC

Registry NCT05074940

Phase Phase 2

Status Active, not recruiting

Enrollment 21

Start 2022-08-05

Primary completion 2026-03-02

Study completion 2028-08-05

Catalyst Primary completion. 03.02.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Amivantamab

Dose not stated in source

Population ACC (n = 21)

Estimand Single arm

responders: 1 patients (of 21), results posted 05.08.2026

median progression-free survival: 4.6 months, results posted 05.08.2026

patients with serious adverse events: 7 patients (of 21), results posted